Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy

Elise A. Chong, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Nicole Winchell, Daniel J. Landsburg, MD, Anthony R. Mato, MD, Simon F. Lacey, PhD, Jan J. Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2016) 128 (22): 1100.

https://doi.org/10.1182/blood.V128.22.1100.1100

Published: 2016

Journal Articles

Treatment with Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) Results in Durable Remissions in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphomas of Germinal Center and Non-Germinal Center Origin, "Double Hit" Diffuse Large B Cell Lymphomas, and Transformed Follicular to Diffuse Large B Cell Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Elise A. Chong, MD, Nicole Winchell, Daniel J. Landsburg, MD, David L. Porter, MD, Anthony R. Mato, MD, Honore T Strauser, April M. Schrank-Hacker, Mariusz A Wasik, MD, Simon Francis Lacey, PhD BS, Jan Joseph Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Carl H June, MD

Blood (2016) 128 (22): 3026.

https://doi.org/10.1182/blood.V128.22.3026.3026

Published: 2016

Journal Articles

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Elise A. Chong, MD, Daniel J. Landsburg, MD, Anthony R. Mato, MD MSCE, Simon F. Lacey, PhD BS, Jan J. Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Gaurav D. Shah, MD, Mariusz A. Wasik, MD, Katherine T. Marcucci, PhD, Zhaohui Zheng, MS, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2015) 126 (23): 183.

https://doi.org/10.1182/blood.V126.23.183.183

Published: 2015

Journal Articles

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Blood (2014) 124 (21): 3087.

https://doi.org/10.1182/blood.V124.21.3087.3087

Published: 2014

Journal Articles

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

Blood (2014) 124 (21): 1982.

https://doi.org/10.1182/blood.V124.21.1982.1982

Published: 2014

Journal Articles

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

Blood (2014) 124 (21): 1983.

https://doi.org/10.1182/blood.V124.21.1983.1983

Published: 2014

Journal Articles

T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL

Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Pamela Shaw, PhD, Richard Aplenc, MD PhD, David M. Barrett, MDPhD, Colleen Callahan, MSN, CRNP, Anne Chew, PhD, Simon F. Lacey, PhD BSc, Bruce L. Levine, PhD, J. Joseph Melenhorst, PhD, Laura Motley, RN, BSN, Susan R. Rheingold, MD, Angela Shen, MD, David T. Teachey, MD, Patricia A. Wood, MD PhD, David L Porter, MD, Carl H. June, MD

Blood (2014) 124 (21): 380.

https://doi.org/10.1182/blood.V124.21.380.380

Published: 2014

Journal Articles

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL

David L. Porter, MD, Michael Kalos, PhD, Noelle V. Frey, MD, Stephan A. Grupp, MD, PhD, Alison W. Loren, MD, Christina Jemison, RN, Joan Gilmore, Holly McConville, RN, BSN, James Capobianchi, Lester Lledo, CRNP, Anne Chew, PhD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2013) 122 (21): 4162.

https://doi.org/10.1182/blood.V122.21.4162.4162

Published: 2013

Journal Articles

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

David L. Porter, MD, Michael Kalos, PhD, Noelle V. Frey, MD, Stephan A Grupp, MD, PhD, Alison W. Loren, MD, Christina Jemision, RN, Joan Gilmore, Holly McConville, RN, BSN, James Capobianchi, Lester Lledo, CRNP, Anne Chew, PhD, Angela Shen, MD, Patricia A. Wood, MD, PhD, Manuel Litchman, MD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2013) 122 (21): 873.

https://doi.org/10.1182/blood.V122.21.873.873

Published: 2013

Journal Articles

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

Stephan A Grupp, MD, PhD, Noelle V. Frey, MD, Richard Aplenc, MD, PhD, David M Barrett, MD/PhD, Anne Chew, PhD, Michael Kalos, PhD, Bruce L. Levine, PhD, Manuel Litchman, MD, Shannon L Maude, MD, PhD, Susan R. Rheingold, Angela Shen, MD, Christine Strait, David T. Teachey, MD, Patricia A. Wood, MD, PhD, David Porter, MD, Carl H. June, MD

Blood (2013) 122 (21): 67.

https://doi.org/10.1182/blood.V122.21.67.67

Published: 2013

Journal Articles

Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells

Blood (2012) 120 (21): 352.

https://doi.org/10.1182/blood.V120.21.352.352

Published: 2012

Journal Articles

CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).

Stephan A. Grupp, MD, PhD, David L Porter, MD, David T Teachey, MD, David M. Barrett, MD/PhD, Anne Chew, PhD, Erica Suppa, Bruce L. Levine, PhD, Michael Kalos, PhD, Carl H. June, MD

Blood (2012) 120 (21): 2604.

https://doi.org/10.1182/blood.V120.21.2604.2604

Published: 2012

Journal Articles

Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL

David L Porter, MD, Stephan A. Grupp, MD, PhD, Michael Kalos, PhD, Alison W. Loren, MD, Lester Lledo, CRNP, Joan Gilmore, Michael C Milone, MD, PhD, Anne Chew, PhD, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2012) 120 (21): 717.

https://doi.org/10.1182/blood.V120.21.717.717

Published: 2012

Journal Articles

Schedule Dependent Effects of Adoptively Transferred Autologous T Cells After AutoSCT for Myeloma: Accelerated Immune Recovery Is Associated with Improved Event-Free Survival.

Blood (2009) 114 (22): 784.

https://doi.org/10.1182/blood.V114.22.784.784

Published: 2009

Journal Articles

Influenza (flu) Vaccine Administration to Patients with Multiple Myeloma (MM) Prior to Autologous T-Cell Harvest Leads to Better Reconstitution of Flu Immunity After High Dose Melphalan and Autologous Stem Cell Transplant (ASCT) and Reinfusion of Primed Ex-Vivo Co-Stimulated Autologous T-Cells and Post-ASCT Second Flu Vaccination Than Post-ASCT Flu Vaccination Alone.

Edward A. Stadtmauer, MD, Dan T. Vogl, MD, Nicole A. Aqui, MD, Aaron P. Rapoport, MD, Kenyetta Macdonald, Heather Murphy, Rita Bhagat, RN, Patricia A. Mangan, APRN, BC, Anne Chew, PhD, Elizabeth Veloso, RN, JD, Bruce Levine, PhD, Robert H. Vonderheide, MD, DPhil, Carl H. June, MD, Kathleen Sullivan, MD

Blood (2009) 114 (22): 797.

https://doi.org/10.1182/blood.V114.22.797.797

Published: 2009

Journal Articles

Rapid T Cell Recovery and Possible Auto-GVHD Following Adoptive Transfer of Ex-Vivo Costimulated Autologous T Cells at Day +2 Post-Transplant.

Aaron P. Rapoport, MD, Stephan A. Grupp, MD, PhD, Edward A. Stadtmauer, MD, Robert H. Vonderheide, MD, PhD, Bruce L. Levine, PhD, Hongbin Fang, PhD, Kelly Yager, RN, Anne Chew, PhD, Elizabeth Veloso, RN, Carl H. June, MD

Blood (2007) 110 (11): 769.

https://doi.org/10.1182/blood.V110.11.769.769

Published: 2007

NARROW

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells

CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).

Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL

Schedule Dependent Effects of Adoptively Transferred Autologous T Cells After AutoSCT for Myeloma: Accelerated Immune Recovery Is Associated with Improved Event-Free Survival.

Rapid T Cell Recovery and Possible Auto-GVHD Following Adoptive Transfer of Ex-Vivo Costimulated Autologous T Cells at Day +2 Post-Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only